Adam Mullick, Ph.D.Vice President, Cardiovascular Drug Discovery at Ionis Pharmaceuticals
Dr. Mullick is currently a Vice President of Cardiovascular and Renal Drug Discovery at Ionis Pharmaceuticals. Dr. Mullick contributed to the early development of Kynamro®, WAYLIVRA®, AKCEA-APOCIII-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APO(a)-LRx and led the research efforts for IONIS-AGT-LRx currently in clinical development for treatment-resistant hypertension and heart failure. His current research efforts include preclinical development of targets for heart failure and renal disease in addition to leading the efforts to identify methods to enhance heart oligonucleotide delivery. Dr. Mullick earned his Ph.D. in Molecular, Cellular & Integrative Physiology from UC Davis and was a postdoctoral fellow in the Department of Immunology at The Scripps Research Institute before joining Ionis Pharmaceuticals in 2007.